FibroGen Inc (NASDAQ:FGEN) – Equities research analysts at Piper Jaffray Companies raised their Q2 2019 EPS estimates for FibroGen in a research note issued on Monday, May 27th. Piper Jaffray Companies analyst D. Brill now anticipates that the biopharmaceutical company will post earnings of ($0.65) per share for the quarter, up from their previous forecast of ($0.66). Piper Jaffray Companies has a “Positive” rating and a $40.00 price objective on the stock. Piper Jaffray Companies also issued estimates for FibroGen’s Q3 2019 earnings at ($0.46) EPS, FY2019 earnings at ($1.06) EPS, Q1 2020 earnings at ($0.67) EPS, Q2 2020 earnings at ($0.74) EPS, Q3 2020 earnings at ($0.08) EPS, Q4 2020 earnings at $0.51 EPS, FY2020 earnings at ($0.89) EPS, FY2021 earnings at ($1.11) EPS and FY2022 earnings at ($0.83) EPS.
FibroGen (NASDAQ:FGEN) last released its quarterly earnings data on Thursday, May 9th. The biopharmaceutical company reported ($0.53) earnings per share for the quarter, beating the consensus estimate of ($0.68) by $0.15. FibroGen had a negative return on equity of 17.71% and a negative net margin of 44.14%. The company had revenue of $23.90 million for the quarter, compared to analyst estimates of $20.44 million. During the same period in the prior year, the company posted ($0.50) EPS. The company’s revenue was down 25.1% compared to the same quarter last year.
Several other research analysts also recently commented on FGEN. Zacks Investment Research downgraded FibroGen from a “buy” rating to a “hold” rating in a report on Wednesday, May 15th. TheStreet downgraded FibroGen from a “c-” rating to a “d+” rating in a report on Friday, May 24th. Goldman Sachs Group reissued a “neutral” rating and issued a $45.00 target price on shares of FibroGen in a report on Wednesday. ValuEngine downgraded FibroGen from a “buy” rating to a “hold” rating in a report on Friday, May 10th. Finally, BidaskClub downgraded FibroGen from a “strong-buy” rating to a “buy” rating in a report on Friday, February 22nd. One equities research analyst has rated the stock with a sell rating, four have assigned a hold rating and five have given a buy rating to the company. The stock presently has a consensus rating of “Hold” and an average target price of $61.57.
FGEN stock opened at $36.24 on Thursday. The company has a market capitalization of $3.12 billion, a PE ratio of -35.18 and a beta of 1.60. The company has a debt-to-equity ratio of 0.09, a quick ratio of 6.16 and a current ratio of 6.16. FibroGen has a 1-year low of $33.51 and a 1-year high of $68.55.
In other FibroGen news, CEO Thomas B. Neff sold 39,636 shares of the company’s stock in a transaction on Thursday, May 23rd. The stock was sold at an average price of $35.37, for a total transaction of $1,401,925.32. Following the transaction, the chief executive officer now owns 2,503,912 shares of the company’s stock, valued at approximately $88,563,367.44. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. Also, Director James A. Schoeneck sold 2,000 shares of the company’s stock in a transaction on Thursday, March 7th. The stock was sold at an average price of $54.74, for a total value of $109,480.00. Following the transaction, the director now directly owns 29,700 shares in the company, valued at approximately $1,625,778. The disclosure for this sale can be found here. Insiders sold a total of 256,640 shares of company stock worth $12,322,748 over the last three months. 8.96% of the stock is owned by company insiders.
A number of large investors have recently bought and sold shares of FGEN. JPMorgan Chase & Co. lifted its holdings in FibroGen by 9.1% during the 3rd quarter. JPMorgan Chase & Co. now owns 1,158,474 shares of the biopharmaceutical company’s stock worth $70,378,000 after buying an additional 97,070 shares in the last quarter. Vanguard Group Inc lifted its holdings in FibroGen by 1.8% during the 3rd quarter. Vanguard Group Inc now owns 6,921,874 shares of the biopharmaceutical company’s stock worth $420,503,000 after buying an additional 125,186 shares in the last quarter. Meeder Asset Management Inc. lifted its holdings in FibroGen by 622.4% during the 4th quarter. Meeder Asset Management Inc. now owns 614 shares of the biopharmaceutical company’s stock worth $28,000 after buying an additional 529 shares in the last quarter. Bank of Montreal Can lifted its holdings in FibroGen by 177.3% during the 4th quarter. Bank of Montreal Can now owns 1,722 shares of the biopharmaceutical company’s stock worth $80,000 after buying an additional 1,101 shares in the last quarter. Finally, Assenagon Asset Management S.A. acquired a new position in FibroGen during the 4th quarter worth $2,165,000. 66.27% of the stock is currently owned by hedge funds and other institutional investors.
FibroGen, Inc, a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. It is developing Roxadustat, an oral small molecule inhibitor of hypoxia inducible factor prolyl hydroxylases (HIF-PHs) that is in Phase III clinical development for the treatment of anemia in chronic kidney disease in the United States and Europe; and in Phase II/III development in China for anemia associated with myelodysplastic syndromes.
Read More: S&P 500 Index
Receive News & Ratings for FibroGen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for FibroGen and related companies with MarketBeat.com's FREE daily email newsletter.